Страница 1 от 893 резултата
A 1977 College of American Pathologists survey of hospitals has been analyzed to compare Rh immune globulin usage (RhIgG) with methods used to screen and confirm fetomaternal hemorrhage (FMH). The survey data show that there is a correlation between the rate of multiple vial usage and the
Current serologic tests occasionally fail to identify women needing more than one vial of Rh immune globulin. We compared the indirect antiglobulin test after incubation with anti-D and a rosetting technique using enzyme treated Rh2Rh2 erythrocytes as methods for identifying significant fetal
BACKGROUND
Fetal-maternal hemorrhage is usually spontaneous and goes undetected but can be associated with adverse perinatal outcomes.
METHODS
We describe the detection of a fetal-maternal hemorrhage by abrupt disappearance of prophylactic anti-D on antibody screen in an Rh-negative mother with
Dengue hemorrhagic fever (DHF) is a potentially lethal complication of mosquito borne viral disease, Dengue Fever. Thrombocytopenia is a constant finding in DHF/Dengue Shock Syndrome (DSS). We report two cases that fulfilled the WHO criteria of DSS: high fever, positive tourniquet test, severe
The inadequacy of current testing methods for fetal-maternal hemorrhage (FMH) had led to the use of postinjection titers of Rh immune globulin (RhIg) to assess large FMH. The authors have studied the titers of 30 RhIg recipients who received 300 micrograms of RhIg. The 48-hour postinjection titer
An enzyme-linked antiglobulin test has been developed to detect and quantitate fetal-maternal hemorrhage. The test is applicable to postpartum screening of Rh immune globulin candidates. The enzyme-linked antiglobulin test has greater sensitivity than agglutination tests; it has fewer false positive
We report a case of acquired von Willebrand's disease with severe and persistent gastro-intestinal bleeding from multiple bleeding points. He received maximum substitution treatment including factor VIII concentrates, cryoprecipitate and platelets. He also received DDAVP. There was no change in the
After a traffic accident, causing intracranial haemorrhage in a 15-year-old boy with moderately severe haemophilia A, severe bleeding sequelae could not be prevented despite satisfactory substitution with lyophilized antihaemophilic globulin. The bleeding was probably due to a platelet abnormality
Tests on 16 patients with haemophilia A confirmed earlier studies that bleeding times may be prolonged after treatment with antihaemophilic globulin (AHG). Despite adequate factor VIII substitution by AHG, treatment effect was unsatisfactory in all 16 patients and there were abnormally prolonged
BACKGROUND
Hemorrhagic cystitis (HC) is a complication of allogeneic stem cell transplantation (SCT), associated with factors such as BK polyomavirus reactivation, age, conditioning regimen, and presence of graft-versus-host disease (GVHD). The incidence and impact of HC in patients receiving
Severe thrombocytopenia and increased vascular permeability are two major characteristics of dengue hemorrhagic fever (DHF). An immune mechanism of thrombocytopenia due to increased platelet destruction appears to be operative in patients with DHF (see Saito et al., 2004, Clin Exp Immunol 138:
BACKGROUND
Rh(D)-negative women with a large fetomaternal hemorrhage (FMH) from an Rh(D)-positive fetus are at risk for anti-D alloimmunization if they do not receive adequate Rh immune globulin (RhIG). Determination of the adequate RhIG dose for these women is a critical laboratory procedure for
Previous studies have identified a diverse set of predisposing factors for the occurrence of hemorrhagic transformation (HT), but the independent clinical predictors of HT after intraarterial thrombolysis have not been determined. In this retrospective study, we investigated the characteristics of
Dengue hemorrhagic fever (DHF) is a potentially lethal complication of dengue fever due to shock and/or bleeding. Bleeding in DHF is due to thrombocytopenia and/or coagulopathy. The authors present their experience of usage of intravenous anti-D in 5 children with DHF and severe refractory